Actually for the group of subjects with baseline MMSE scores less than 20 Anavex 2-73 Blarcamesine did better than the current SOC Standard of Care which is donepezil (Aricept) and/or memantine.
FAKE ANALYSIS: And anavex failed every single patient scoring under 20. That has not been established for SAVA but HAS for anavex who is NO LONGER seeking that demographic .
What do you mean "no longer seeking"? Or did you forget ANavex has a 450 person P3 trial speeding toward completion?
The new trial is to expand the scope of patients to whom 273 could be given to as a preventative.
Market Data 
Markets 
AI
